Who Is Dr. Adi Zuloff-Shani? Chief Executive Officer of Clearmind Medicine
Overview and statements from the Chief Executive Officer of Clearmind Medicine.
Dr. Adi Zuloff-Shani serves as the Chief Executive Officer of Clearmind Medicine.
At Mind Medicine Law, we track the people building legal, evidence-based access to psychedelic medicine: the companies running the trials, the researchers and advocates behind them, and the officials who write and run the laws.
Dr. Zuloff-Shani holds a Ph.D. and is known for a collaborative leadership style.
Where Dr. Adi Zuloff-Shani Is Now
- Current role: Chief Executive Officer
- Organization: Clearmind Medicine
- Known for: A collaborative leadership style
- Recent news: Described Yale IRB approval for Parts B and C as an important milestone for the CMND-100 clinical program
Dr. Adi Zuloff-Shani currently serves as the Chief Executive Officer of Clearmind Medicine, as reported by Business Insider.
Background and Leadership
Dr. Zuloff-Shani holds a Ph.D., according to Nasdaq.
She is known for a collaborative leadership style, and her ideas regarding harmonization among regulators, legislators, and the biopharma sector were featured in Psychology Today, as documented by FinancialContent.
Statements on CMND-100 Development
Zuloff-Shani stated that Clearmind remains committed to science-driven development of lead candidate CMND-100 (MEAI) and its broader pipeline, per Nasdaq. She also stated that CMND-100 represents a promising new approach to aid people struggling with alcohol use disorder and binge behaviors, as noted by StreetInsider.
According to Nasdaq, Zuloff-Shani stated that Clearmind is building evidence for CMND-100 as a treatment for alcohol use disorder that is non-hallucinogenic and not adjunct to psychotherapy. She described Yale IRB approval for Parts B and C as an important milestone for the CMND-100 clinical program, stating that the clearance allowed Clearmind to immediately expand and accelerate patient recruitment alongside Johns Hopkins and Israeli medical centers, as reported by the Financial Times.
Engagement with Federal Initiatives and Policy
Zuloff-Shani stated that Clearmind has been dedicating substantial resources and effort to advancing awareness of non-hallucinogenic neuroplastogens and their potential role in addressing significant unmet needs in addiction and mental health, according to Business Insider. She added that Clearmind's engagement with the U.S. federal government reflects its commitment to dialogue on patient access and responsible development.
Regarding national initiatives, Zuloff-Shani stated that President Trump's Executive Order aligned with Clearmind's mission to develop psychedelic-derived therapies that do not produce hallucinogenic experiences, according to Nasdaq. Furthermore, she stated that Clearmind was proud to provide its clinical insights and data to the federal addiction treatment initiative, as reported by StreetInsider.
Frequently asked questions
Who is Dr. Adi Zuloff-Shani?
Dr. Adi Zuloff-Shani is the Chief Executive Officer of Clearmind Medicine and holds a Ph.D.
What leadership style is Dr. Adi Zuloff-Shani known for?
Dr. Zuloff-Shani is known for a collaborative leadership style.
Where were Dr. Zuloff-Shani's ideas on sector harmonization featured?
Her ideas regarding harmonization among regulators, legislators, and the biopharma sector were featured in Psychology Today.
What has Dr. Zuloff-Shani stated about CMND-100?
Zuloff-Shani stated that CMND-100 represents a promising new approach to aid people struggling with alcohol use disorder and binge behaviors, and that Clearmind is building evidence for it as a non-hallucinogenic treatment that is not adjunct to psychotherapy.
What did Dr. Zuloff-Shani say regarding Yale IRB approval?
She described Yale IRB approval for Parts B and C as an important milestone that allowed Clearmind to immediately expand and accelerate patient recruitment alongside Johns Hopkins and Israeli medical centers.
What has Dr. Zuloff-Shani stated regarding non-hallucinogenic neuroplastogens?
She stated that Clearmind has dedicated substantial resources and effort to advancing awareness of non-hallucinogenic neuroplastogens and their potential role in addressing significant unmet needs in addiction and mental health.
Sources
General information compiled from the public reporting cited above, not medical or legal advice. Mention of a treatment, trial or bill is not a claim that it is safe, effective or legal where you live. Not endorsed by or affiliated with Dr. Adi Zuloff-Shani or Clearmind Medicine. See more people in psychedelic medicine.